Virginia Kaklamani, MD

Articles

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

August 6th 2024

A panel of experts offer future perspectives in HR+ breast cancer.

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

August 6th 2024

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

July 29th 2024

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

July 29th 2024

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

July 29th 2024

A panel of experts discuss navigating 2L treatment strategies.

Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

July 29th 2024

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

July 8th 2024

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

June 25th 2024

Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

June 25th 2024

Leading oncologists explore optimal biomarker testing strategies for early-stage breast cancer, examining the comparative advantages of tissue and liquid biopsies to guide personalized treatment decisions.

Advice For Providers Caring for Patients With HR+/HER2- mBC

October 10th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.

Remaining Unmet Needs for Patients With HR+/HER2- mBC

October 10th 2023

Experts highlight some remaining unmet needs in the treatment and management of patients with HR+/HER2- metastatic breast cancer.

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC

October 3rd 2023

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.

Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC

October 3rd 2023

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.

Safety and Efficacy of Sacituzumab Govitecan in the Treatment of HR+/HER2- mBC

September 26th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, Diaz review the available safety and efficacy data from the TROPiCS-02 trial on the use of antibody drug conjugate sacituzumab govitecan for the treatment of HR+/HER2- metastatic breast cancer.

Case Presentation: A 56-Year-Old Woman With ER+/HER2- mBC

September 26th 2023

Virginia Kaklamani, MD, presents the case of a 56-year-old postmenopausal woman diagnosed with ER+/HER2- metastatic breast cancer for discussion.

Antibody Drug Conjugates in the Treatment of Endocrine-Resistant HR+/HER2- mBC

September 19th 2023

Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.

Treatment Options for Patients with Endocrine-Resistant HR+/HER2- mBC

September 19th 2023

Experts discuss the complexity of defining endocrine resistance in patients with HR+/HER2- metastatic breast cancer and the options for treatment.